Key Takeaways
- Subdued H1, cautious tone: H1 volume growth was only marginally up YoY, and full-year FY26 volume growth is expected to be subdued versus the normal 10-15% pace. Management attributes the softness to global trade volatility and US tariff uncertainty making customers nervous.
- Acetonitrile anti-dumping duty is a delayed catalyst: The duty took effect end-June, but pre-duty import inventory is still clearing and aggressive Chinese pricing has muted price improvement. Management expects the real volume benefit to materialize only from Q4 onwards.
- Methylamines face a structural overhang: A fourth domestic player has commissioned its plant, and management concedes methylamines is "going to be a long item for some time to come yet" due to the capacity overhang.
- Margins are protected despite top-line pressure: Contribution per kg is "fairly protected" and gross margins are "almost stable," with ethylamines' selling-price decline offset by methylamines' volume loss.
- What to watch next quarter: Whether the Q4 acetonitrile volume benefit starts to show early signs, any stabilization in global trade sentiment that could unlock constrained demand, and progress on the new import-substitute product's mechanical completion.
Demand Environment & Volume Outlook
- H1 volume subdued: Volume growth in the first half was only marginally up versus H1 last year, with full-year FY26 volume growth expected to fall short of the normal 10-15% range.
- Global trade anxiety is the root cause: US government policy volatility and tariff uncertainty have made customers nervous, constraining demand across pharma and other industries. Management believes demand could change if the situation settles.
- AgroChem and pharma both soft: Demand across agrochemicals and pharmaceuticals is currently "not great," with variation molecule to molecule. DEK's end-use agrochemical molecule, which was under pressure, has now returned to normal, though margins are lower than expected.
- Normalization, not collapse: The company is now on its pre-COVID trend line; COVID was an outlier above the trend, and current volumes and profitability are already above 2019 levels. On the current run rate, total sales volume will cross 100,000 tons.
Kirat Patel: "right now in this first half, because of all the ups and downs of the US government, people are a bit nervous and demand is a little constrained. But that could change if all gets settled."
Acetonitrile: The Delayed Catalyst
- Anti-dumping duty effective, but inventory overhang persists: The duty became effective end-June, but pre-duty imports were 1.5-2x normal levels. That inventory was still clearing through the July-September quarter, so prices improved only marginally.
- Chinese aggression mutes price upside: Chinese producers are dropping prices further, making the price outlook uncertain. Management expects the real benefit to be volume-led, not price-led.
- Timing pushed to Q4: Management stated, "Fourth quarter onwards, we will see real benefit coming in. Mainly volume."
- GLP-1 opportunity is early-stage: Acetonitrile is used in peptide-based diabetic and weight-loss drugs. The company has secured some approvals from manufacturers, but demand potential is early-stage and uncertain. Management deflected a question on usage across GLP-1 drugs beyond semaglutide, saying they lack that product-level knowledge.
- Capacity expansion is conditional: If the market grows and capacity utilization warrants it, the company may add capacity. Management noted that many players have voiced expansion desires over the last four years but few have actually appeared in the market. If full utilization is achieved in 2-3 years, expansion would follow, but it is a large investment decision.
Kirat Patel: "If we are lucky enough to have full utilization in 2-3 years, we will also expand. But let us see, it is a long way. I mean, there have been a lot of people who have voiced their desire to expand acetonitrile over the last four years. How many have they actually turned up in the market? So, you have seen that."
Product-Level Dynamics
- Methylamines vs ethylamines divergence: Methylamines were more impacted than ethylamines, losing volumes. Ethylamines are largely domestic with domestic competition, so they were less affected, though both have some demand impact from pharma customers' global demand.
- Contribution protected despite mix shift: Ethylamines contribution per kg fell because selling prices declined, while methylamines lost volumes. Overall contribution is "fairly protected" and gross margins are "almost stable."
- Methylamines structural overhang: A fourth domestic player, Aarti Drugs, has commissioned its plant and will soon enter the market. Management stated methylamines "is going to be a long item for some time to come yet" due to the capacity overhang. The company declined to quantify volumes sold through Aarti Drugs.
- DEK plant stabilized: The DEK plant is now running at reasonably good capacity and is stabilized. Volumes are catching up, though margins are lower than expected. Management expressed cautious optimism for the next half.
- DMF not viable: The company is not making DMF because imports are much cheaper; it is not currently viable. Management did not address whether they plan to ever make it.
- Ethylamine headroom: Plant utilization is expected at 60-70%, leaving plenty of headroom for growth.
Kirat Patel: "So methylamines is going to be a long item for some time to come yet."
Trade & Raw Material Headwinds
- US tariffs: small direct hit, indirect unknown: Direct US exposure is approximately 1% of sales. Some products are exempt, while others face 20%, 25%, or 50% duty. Indirect exposure via pharma customers is hard to quantify; management declined to confirm an analyst's estimate of less than 5-6%, calling it "a bit unknown."
- Chinese displacement effect: Chinese producers, blocked from the US market, have become more aggressive in ex-US markets including Asia. Management confirmed they are "pushing it towards Asia or wherever else they can."
- Ammonia supply disruption: US sanctions on Iranian-origin purchases have disrupted supply chains for distributors. Alkyl Amines has not yet felt the impact as materials are covered, but expects a temporary price blip soon, followed by normalization as supply chains readjust. The impact is unlikely to be long-lasting.
- Isopropylamine duty protection in process: The Ministry of Commerce deadline for a recommendation is December, with a Ministry of Finance decision expected by March.
Kirat Patel: "Yes, because what they were probably directing towards the US is now not available to them. So, they are pushing it towards Asia or wherever else they can."
New Product Pipeline & Capex
- Import-substitute product on track: A new product going into dyes, pigments, and electronics is under CAPEX at Kurkumbh. Mechanical completion is expected February-March 2026, with commercialization in Q1 FY27. The technology is claimed to be superior to Chinese alternatives, and there is no domestic manufacturer. The product is expected to be profitable.
- R&D pipeline decisions in 3-6 months: A couple of products are in the pipeline, with investment decisions expected in the next 3-6 months if they look attractive. These products will be in the company's technological area of strength, not necessarily amines or amine derivatives, but similar specialties.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth FY26 | Subdued vs normal 10-15% | Full year FY26 |
| Acetonitrile anti-dumping benefit | Real benefit, mainly volume | "Fourth quarter onwards" (Q4 FY26) |
| New product commercialization | Import-substitute, dyes/pigments/electronics | Q1 FY27 (mechanical completion Feb-Mar 2026) |
| Isopropylamine duty protection | Ministry of Commerce recommendation | December deadline; MoF decision by March |
| New product investment decisions | A couple of products in pipeline | "Next 3 to 6 months" if attractive |
| Demand recovery | Normal growth resumes | Conditional on global trade volatility settling |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue | No absolute revenue figure stated |
| Volume growth (H1 FY26 vs H1 FY25) | Marginally up, below normal expected range of 10% to 15% |
| Gross margins | Almost stable, overall contribution protected |
| Ethylamine plant utilization | 60%–70% expected, commissioned ~1.5 years ago with 30,000 tons capacity |
| Methylamine derivatives share of amine output | ~30% (including isopropyl and methyl derivatives) |
| Direct US export exposure | ~4% of total exports, ~1% of total sales; worst-case direct impact ~1% of topline |
| Total production capacity (all products) | ~2 lakh tons (if everything runs perfectly) |
| Saleable capacity | ~1.5 lakh tons (after removing ~25% internal consumption) |
| New product CAPEX (Kurkumbh) | ₹120 crores, mechanical completion expected Feb–Mar 2026, commercialization Q1 FY27 |
| New product expected asset turnover | ~1.5x turnover-to-asset ratio |
| Acetonitrile current sales volume | ~15,000–16,000 tons |
| Acetonitrile projected sales volume (2 years) | ~20,000 tons (assuming current growth rate) |
| Last acetonitrile plant CAPEX | ₹150–160 crores |
| Acetonitrile plant turnaround time | ~2 years (plus ~1 year for environmental clearances) |
| DEK capacity | ~5 tons per day |